Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 44.48B |
| Revenue (ttm) | 10.37B |
| Net Income (ttm) | 3.25B |
| Shares Out | n/a |
| EPS (ttm) | 28.96 |
| PE Ratio | 13.67 |
| Forward PE | 13.64 |
| Dividend | 2.01 (0.34%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 229 |
| Average Volume | 1,293 |
| Open | 590.00 |
| Previous Close | 585.59 |
| Day's Range | 585.53 - 596.66 |
| 52-Week Range | 477.01 - 1,210.92 |
| Beta | n/a |
| RSI | 52.20 |
| Earnings Date | Aug 1, 2025 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Regeneron Pharmaceuticals declares $0.88 dividend
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported upbeat second- quarter earnings . The company posted adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consen...
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings.
Is Regeneron Pharmaceuticals Gaining or Losing Market Support?
Regeneron Pharmaceuticals's (NYSE: REGN) short percent of float has fallen 7.73% since its last report. The company recently reported that it has 2.07 million shares sold short , which is 2.03% of al...
Regeneron (REGN) Q2 EPS Jumps 53%
Regeneron: Rapidly Decreasing Importance Of Eylea
Smart Money Is Betting Big In REGN Options
Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ: REGN). And retail traders should know. We noticed this today when the trades showed up on publ...
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
US FDA declines to approve Regeneron's blood cancer therapy for second time
Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator's inspection at a t...
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
On Friday, Regeneron Pharmaceuticals Inc . (NASDAQ: REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57 . The company reported s...
4 stocks to watch on Friday: PLTR, XOM, CVX, REGN
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Regeneron beats second-quarter results estimates on Dupixent sales boost
Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up nearl...
Regeneron posts Q2 beat as new Eylea version outperforms
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Regeneron Reports Second Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update.
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Regeneron Pharmaceuticals, Inc . (NASDAQ: REGN) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1. Analysts expect the Tarrytown, New York -based company...
Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Regeneron Pharmaceuticals, Inc. REGN will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.
Earnings Scheduled For August 1, 2025
Companies Reporting Before The Bell • Brookfield Business (NYSE: BBUC) is expected to report earnings for its second quarter. • TELUS (NYSE: TU) is likely to report quarterly earnings at $0.17 per s...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.